Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added Revision: v3.4.3; removed Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-08T04:41:08.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.1 to v3.4.2. This appears to be a version control update with no visible changes to study information or page layout.
    Difference
    0.0%
    Check dated 2026-02-14T13:14:56.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision updated from v3.4.0 to v3.4.1. This appears to be a minor technical update without changes to the study content or user-facing features.
    Difference
    0.0%
    Check dated 2026-02-07T07:42:16.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Added a Show glossary option and updated the page revision to v3.4.0. Capitalization and wording were updated for 'No FEAR Act Data' and 'Last Update Submitted that Met QC Criteria' (replacing the previous 'Last Update Submitted that met QC Criteria').
    Difference
    0.1%
    Check dated 2026-01-24T01:28:52.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Revision label on the page changed from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-17T01:19:22.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    The Locations section now lists numerous participating sites across the United States, Canada, Australia, and various European and Asian countries.
    Difference
    5%
    Check dated 2025-12-19T10:16:40.000Z thumbnail image

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.